Document Detail


Preoperative p53, bcl-2, CD44 and E-cadherin immunohistochemistry as predictors of biochemical relapse after radical prostatectomy.
MedLine Citation:
PMID:  10081877     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: Since radical prostatectomy is performed to cure prostate cancer, identification of markers enabling preoperative prediction of relapse after radical prostatectomy is essential to counsel and select patients for adjuvant therapy. Aberrant p53, bcl-2, CD44 and E-cadherin immunohistochemistry has been associated with aggressiveness in prostate cancer. We assessed these biomarkers in biopsy and radical prostatectomy specimens as predictors of biochemical relapse. MATERIALS AND METHODS: A total of 76 patients with untreated clinically localized prostatic adenocarcinoma underwent radical prostatectomy. Preoperative (prostate specific antigen, biopsy Gleason score) and postoperative (pathological stage and margin status) variables, biopsy and radical prostatectomy biomarker immunohistochemistry were correlated with relapse. Univariate and multivariate statistical analyses identified significant predictors. RESULTS: Of the 76 patients 23 (30%) had relapse (mean followup 38 months). Aberrant p53, bcl-2, CD44 and E-cadherin expression was observed in 64, 12, 85 and 12% of biopsies and 57, 20, 64 and 49% of radical prostatectomy specimens, respectively. Biopsy Gleason 7 to 10 and biopsy p53, respectively, gave the highest positive and negative predictive values for relapse. Relapse occurred in 13% of patients with normal biopsy p53 and in half with aberrant p53. Multivariate analysis revealed Gleason score and p53 to be independent preoperative predictors (p = 0.01 and 0.02, respectively). Estimated risk of relapse was 3.5 times higher in patients with Gleason scores 7 to 10 and 24% higher in those with aberrant p53. Significant postoperative predictors were bcl-2, p53, Gleason score and margin status (p = 0.01, 0.01, 0.04 and 0.01, respectively). CONCLUSIONS: Aberrant biopsy p53 is associated with a significantly worse outcome after radical prostatectomy than normal p53, highlighting a potential clinical role for p53. Postoperative p53 and bcl-2 were significant predictors of outcome after radical prostatectomy.
Authors:
S F Brewster; J D Oxley; M Trivella; C D Abbott; D A Gillatt
Related Documents :
17414097 - Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and im...
18754867 - Estimation of the relationship between caspase-3 expression and clinical outcome of bur...
9655287 - P53 sequence analysis predicts treatment response and outcome of patients with esophage...
17468917 - Adenocarcinoma of the ampulla of vater: t-stage, chromosome 17p allelic loss, and exten...
15321037 - Management and outcome of extremity soft tissue sarcomas.
8865487 - Mr characterization of post-irradiation soft tissue edema.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The Journal of urology     Volume:  161     ISSN:  0022-5347     ISO Abbreviation:  J. Urol.     Publication Date:  1999 Apr 
Date Detail:
Created Date:  1999-04-16     Completed Date:  1999-04-16     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0376374     Medline TA:  J Urol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1238-43     Citation Subset:  AIM; IM    
Affiliation:
Bristol Urological Institute, Department of Cellular Pathology, Southmead Hospital, University of Bristol, United Kingdom.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Antigens, CD44 / analysis*
Cadherins / analysis*
Genes, bcl-2
Humans
Immunohistochemistry
Male
Middle Aged
Neoplasm Recurrence, Local / chemistry*,  mortality
Postoperative Care
Predictive Value of Tests
Preoperative Care
Prostatectomy*
Prostatic Neoplasms / chemistry*,  mortality,  surgery
Proto-Oncogene Proteins c-bcl-2 / analysis*
Risk Factors
Survival Rate
Tumor Suppressor Protein p53 / analysis*
Chemical
Reg. No./Substance:
0/Antigens, CD44; 0/Cadherins; 0/Proto-Oncogene Proteins c-bcl-2; 0/Tumor Suppressor Protein p53

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Androgen receptor expression in prostate cancer lymph node metastases is predictive of outcome after...
Next Document:  Retrovesical mass in men: pitfalls of differential diagnosis.